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Objective: To date, only a small number of epidemiological studies on myelofibrosis have been performed.
The current study aimed to characterize the myelofibrosis patient population in Belgium according to pre-
defined disease parameters (diagnosis, risk categories, hemoglobin ,10 g/dl, spleen size, constitutional
symptoms, platelet count, myeloblast count), with a view to obtaining a deeper understanding of the
proportion of patients that may benefit from the novel myelofibrosis therapeutic strategies.
Methods: A survey was used to collect data on prevalence and disease parameters on all myelofibrosis
patients seen at each of 18 participating hematologic centers in 2011. Aggregated data from all centers
were used for analysis. Analyses were descriptive and quantitative.
Results: A total of 250 patients with myelofibrosis were captured; of these, 136 (54%) were male and 153
(61%) were over 65 years old. One hundred sixty-five (66%) of myelofibrosis patients had primary
myelofibrosis and 85 (34%) had secondary myelofibrosis. One hundred ninety-three myelofibrosis
patients (77%) had a palpable spleen. About a third of patients (34%) suffered from constitutional
symptoms. Two hundred twenty-two (89%) myelofibrosis patients had platelet count§50 000/ml and 201
(80%) had platelet count§100 000/ml. Of 250 patients, 85 (34%) had a myeloblast count§1%. Six (2%)
patients had undergone a splenectomy. Thirteen (5.2%) patients had undergone radiotherapy for
splenomegaly.
Conclusions: The results of this survey provide insight into the characteristics of the Belgian myelofibrosis
population. They also suggest that a large proportion of these patients could stand to benefit from the
therapies currently under development.
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Introduction
Primary myelofibrosis (MF), a rare type of myelopro-
liferative neoplasm (MPN), is a life-threatening hema-
tologic malignancy.1 The disease can be a primary
disorder or secondary to pre-existing polycythemia vera
(PPV–MF) and post-essential thrombocythemia (PET–
MF). The disease is characterized by fibrosis of the bone
marrow, enlargement of the spleen, progressive cyto-
penia, leukoerythroblastosis, extramedullary hemato-
poiesis, constitutional symptoms and functional
symptoms as fatigue and itching that can severely
diminish the patient’s quality of life.2,3 The median
overall survival for MF patients is 4 to 6 years from
time of diagnosis.4,5 The major causes of death include
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progressive bone marrow failure, infections and trans-
formation to acute leukemia.6
Published data on the incidence and prevalence of
MF in Europe are limited.5,7–10 Estimates of the
annual incidence of MF in Europe range between 0.3
and 0.6 cases per 100 000 persons.5,7–9 MF is most
commonly diagnosed in patients over the age of 50,7,9
and appears to be more frequent in men.5,7–9
Well-established factors predictive of a poor prog-
nosis of MF include age (.65 years), hemoglobin
concentration (,10 g/dl), leucocyte count (.256109/l),
circulating blasts (.1%) and the presence of one or
more constitutional symptoms. Based on these factors,
the international prognostic scoring system (IPSS) and
the dynamic international prognostic scoring system
(DIPSS) stratify MF patients into four groups: Low,
Intermediate-1 (Int-1), Intermediate-2 (Int-2) and High
risk.6,11 The risk scores are fundamental for risk-based
management strategies in MF. The IPSS score is valid
at diagnosis, while the DIPSS score can be used at any
time during the disease.6,11 Subsequent to the above risk
factors, the ‘DIPSS plus’ scoring system also takes into
account erythrocyte transfusion dependence, thrombo-
cytopenia (,1006109/l) and unfavorable karyotype
(includingz8, -7/7q-, i(17q), inv(3), -5/5q-, 12p-, 11q23
rearrangements and complex karyotypes) as additional
risk factors affecting survival.12
The only potentially curative approach in MF
remains allogeneic hematopoietic stem cell transplanta-
tion (AHSCT). This approach tends to be limited to
High- or Int-2-risk patients younger than 65 years of
age due to a high incidence of morbidity and mortality
associated with the procedure.13–16 Drug therapy in MF
is adjusted to the predominant clinical symptom caused
by anemia, splenomegaly (extramedullary hematopoi-
esis), or constitutional symptoms. Conventional drug
therapy includes androgens, corticosteroids, erythro-
poiesis-stimulating agents (ESAs), danazol, thalido-
mide, lenalidomide and hydroxyurea.1,17,18 Although
splenectomy can temporarily reduce spleen-related
symptoms, the risks associated with surgery do not
qualify it as a routine procedure.19 Splenic irradiation
can be effective for palliating MF-associated spleno-
megaly, but the effects are transient. It can also increase
morbidity and mortality of subsequent splenectomy.20
The discovery and characterization of the JAK2
V617F mutation in 200521–24 in a majority of MF
patients deepened the understanding of the pathogen-
esis of the disease. Subsequent advances in the
development of therapies targeting the major symptoms
of the disease (splenomegaly, burden of constitutional
symptoms)25–27 through inhibition of the JAK-STAT
pathway offer new strategies in the management of MF
patients.28–31
A number of such therapies are now entering clinical
phase development.25–27 Only one of these to date,
ruxolitinib (a JAK1-JAK2 inhibitor), has published
data available on Phase III clinical testing.32 The
clinical benefit of ruxolitinib versus placebo and best
available therapy for MF was demonstrated in two
prospective randomized Phase III clinical trials
(COMFORT I&II).33,34 The US Food and Drug
Administration and European Medicines Agency
granted marketing approval for ruxolitinib for the
treatment of patients with MF in 2011 and 2012,
respectively.34 The US Food and Drug Administration
approved ruxolitinib for the treatment of intermediate
and high risk MF while European Medicines Agency’s
approval is for treatment of disease-related splenome-
galy or symptoms in adult patients with MF (irrespec-
tive of risk score).
The dose limiting toxicities of most JAK inhibitors
tested so far include thrombocytopenia and anemia,31
potentially limiting the proportion of patients eligible
for treatment. CYT387 (momelotinib) could be an
exception, with recent Phase I/II studies suggesting
an improvement in anemia including weaning from
transfusion-dependence.36 This finding still needs to
be confirmed in the ongoing phase III trial where
patients are randomized to momelotinib versus
ruxolitinib treatment (NCT01969838). The current
study was designed to characterize the MF patient
population in Belgium according to a number of
disease parameters (diagnosis, risk categories, spleen
size, constitutional symptoms, platelet count, myelo-
blast count), in view to obtain a better understanding
of the proportion of patients that may benefit from
the therapies currently under development. This ‘real
life’ study involved the majority of the hematological
centers of Belgium and captured all patients visiting
one of the centers during 2011.
Methods
Study design
A scientific survey was designed for investigators to
collect data on Belgian MF patients. The scientific
survey was developed in collaboration with and
endorsed by the MPN subcommittee of the Belgian
Hematological Society. Data were collected for MF
patients who had visited one of 18 major hematology
centers in Belgium at least once during 2011 (see
supplementary methods (Supplementary Material)
for complete list of collaborating centers).
Microsoft Excel worksheets containing questions on
patient details and specific disease-related parameters
(gender, age, cell counts, spleen size, and presence of
constitutional symptoms) and open questions related
to management of their disease were sent to each
participating center between January and March 2012.
A full list of the parameters/questions included is
provided in supplementary methods (Supplementary
Material).
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Data were entered by the investigator directly into
the Microsoft Excel worksheet. Patient data were
based on medical records and were collected for the
most recent visit at the center, whether this was at time
of diagnosis or when already under treatment. For
patients being treated with ruxolitinib, data were taken
from the last visit prior to starting this treatment.
Anonymization and analysis of data
Once all requested information had been entered into
the worksheet, pivot tables automatically consoli-
dated the entered data per site, such that no
individual patients could be identified beyond the
site. Data were submitted for analysis in aggregated
form only. Data from individual sites were then
merged. Analyses were descriptive and quantitative.
Data were analyzed according to disease sub-type
(PMF, PPV–MF or PET–MF), IPSS and DIPSS risk
categories and MF-specific characteristics (spleen
size, the presence of constitutional symptoms, platelet
count and myeloblast count). Both IPSS and DIPSS
scoring systems assign points to five predictive risk
factors: age (.65 years), hemoglobin concentration
(,10 g/dl), leucocyte count (.256109/l), circulating
blasts (.1%) and the presence of one or more
constitutional symptoms.6,11 Each risk factor counts
for one point, except for anemia (hemoglobin
concentration), for which DIPSS assigns two points.
The sum of the points correlates with four risk
groups: IPSS, Low (0 points), Int-1 (1 point), Int-2 (2
points) and High risk (.2 points); DIPSS, Low (0
points), Int-1 (1–2 points), Int-2 (3–4 points) and
High risk (5–6 points).
Results
Demographic characteristics of patients
A total of 250 patients with MF were captured in this
survey; of these, 136 (54%) were male and 153 (61%)
were over 65 years old. One hundred sixty-five (66%)
of MF patients had PMF and 85 (34%) had PET–MF
(57 patients, 23%) or PPV–MF (28 patients, 11%).
The distribution of patients according to disease
characteristics
The distribution of the number of patients (%)
according to IPSS and DIPSS risk categories is
shown in Table 1. Ninety per cent of patients were in
the Int-1 to High risk categories for both the IPSS
and DIPSS. The IPSS showed a roughly equal
distribution between Int-1 (30%), Int-2 (33%) and
High risk (27%) categories for MF patients overall.
For the DIPSS, about half of the patients (49%) fell
into the Int-1 risk category while a considerably
smaller proportion of patients (8%) were categorized
as High risk; a similar proportion of patients to those
in the IPSS were in the Int-2 risk category (34%).
As expected, the proportion of patients in the
Intermediate and High risk categories was higher
for patients older than 65 years than in other patients.
The majority of MF patients (193/250; 77%) had a
palpable spleen. In 81 patients (32%), spleen size was
§10 cm below the costal margin. The proportion of
patients with a palpable spleen tended to increase
with the risk category (up to 82 and 95% in the High
risk category for IPSS and DIPSS, respectively)
(Fig. 1), as did the proportion of patients with a
spleen size§5 cm (and§10 cm) (with the exception
of Int-1 and Int-2 DIPSS categories, for which there
was a similar spleen size distribution).
Most (222/250; 89%) MF patients had a platelet
count§50 000/ml, 201 (90.5%) of whom had platelet
count §100 000/ml. Similar proportions of patients
with high platelet counts were observed when patients
were grouped by age (#65 years or .65 years)
(Table 2). The proportion of patients with a low
platelet count increased with the risk category
(Fig. 2), reflecting the development of thrombocyto-
penia as the disease progresses. There was no
apparent association between spleen size and platelet
count (Fig. 3).
About one-third of patients (86/250; 34%) dis-
played at least one constitutional symptom impacting
prognosis [night sweats, fever or weight loss (.10%
of initial body weight)]. Constitutional symptoms
were reported for the majority of MF patients in the
High risk category (46/67 [69%] for IPSS; 15/19 [79%]
for DIPSS). The spleen was palpable for a slightly
higher proportion of patients with constitutional
symptoms (72/86 [84%]) than with no constitutional
symptoms (121/164 [74%]) (Fig. 4). Moreover, spleen
size §5 cm below the costal margin seemed to be
associated with the presence of constitutional symp-
toms (71% of patients with constitutional symptoms
vs 42% of patients without constitutional symptoms).
Table 1 The distribution of the number of patients (%) among risk categories according to IPSS and DIPSS risk
categories and age classes
Risk category
IPSS DIPSS
Overall N5250 #65 years N597 .65 years N5153 Overall N5250 #65 years N597 .65 years N5153
High 67 (27%) 12 (12%) 55 (36%) 19 (8%) – 19 (13%)
Int-2 82 (33%) 26 (27%) 56 (37%) 84 (34%) 27 (28%) 57 (37%)
Int-1 76 (30%) 34 (35%) 42 (27%) 122 (49%) 45 (46%) 77 (50%)
Low 25 (10%) 25 (26%) – 25 (10%) 25 (26%) –
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The majority of patients had a myeloblast count
,1% (165/250; 66%). Of these, 73 (44%) had a spleen
size §5 cm below the costal margin and 52 (32%)
suffered from constitutional symptoms. Among
patients with a myeloblast count §1% (85/250;
34%), a high proportion (57/85; 67%) had a spleen
size §5 cm below the costal margin and 34 (40%)
suffered from constitutional symptoms.
Platelet counts and splenectomy/spleen
irradiation in MF
Overall, six (2%) patients (none High risk) had
undergone a splenectomy. Of these, four patients
had a platelet count §200 000/ml, one patient had a
platelet count between 75 000 and 100 000/ml, and
one patient had a platelet count ,50 000/ml.
Overall, 13 (5%) patients had undergone radio-
therapy for splenomegaly. Of these, five patients had
a platelet count §200 000/ml, three patients had a
platelet count between 100 000 and 200 000/ml, three
patients had a platelet count between 50 000 and
75 000/ml, and two patients had a platelet count
,50 000/ml.
Discussion
Here we have presented the results of a recently
conducted survey designed to collect quantitative
data to describe prevalence and study-specific disease
parameters (diagnosis, risk categories, spleen size, cell
count, myeloblast count) in Belgian MF patients in
2011.
We aimed to capture the majority of MF patients
in Belgium by targeting 18 major hematology centers
in Belgium. There is likely to be a bias for patients in
the High and Intermediate risk categories as low-risk
patients, with fewer symptoms, may not have been
transferred to these centers. We estimate that the 250
patients captured here represent about 60% of the
total population of MF patients in Belgium in 2011,
considering a PMF prevalence37 of 2.7 per 100 000
(population in 2011: 10.95 million)38 and accounting
for the additional patients with secondary MF (34%
of the total MF population, according to the present
survey). The majority of patients were over 65 years
old, with a slightly higher proportion of men, as
expected.5,7–9
The various symptoms and characteristics of MF
contribute to a diminished quality of life for MF
patients. In particular, splenomegaly, reported for
over three quarters of the patients here, can be
associated with pain, early satiety, bloating and
potentially portal hypertension and portal vein
thrombosis.20
In order to be considered for transplantation, age
and risk category are important selection factors;
older patients are less likely to be considered for
AHSCT due to the toxicity associated with the
procedure. In our survey, 97 out of 250 (39%) MF
patients were #65 years old. Of these, 26 (27%) were
Int-2 and 12 (12%) were High risk IPSS. Thus, only
38 (15.2%) of all patients captured in this survey
would be considered transplant candidates based on
both age and risk category. It should be noted
however that age above 65 is not a strict exclusion
criterion for AHSCT, as each patient should be
Table 2 Platelet count distribution overall and per age class
Platelet count (/ml) Overall N5250 #65 years N597 .65 years N5153
,50 000 28 (11%) 11 (11%) 17 (11%)
§50 000–,75 000 14 (6%) 3 (3%) 11 (7%)
§75 000–,100 000 7 (3%) 3 (3%) 4 (3%)
§100 000–,200 000 58 (23%) 20 (21%) 38 (25%)
§200 000 143 (57%) 60 (62%) 83 (54%)
Figure 1 Distribution of patients according to IPSS or DIPSS risk categories and spleen size: (A) number of patients; (B)
percentages.
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assessed on an individual base and age is not the only
parameter to take into account. Thrombocytopenia is
often present in MF patients and it has been added as
a negative prognostic factor in the DIPSS Plus
scoring system.12 In our survey, severe thrombocyto-
penia was not common. A total of 222 (89%) of the
patients had platelet counts §50 000/ml. Patients
with very low platelet count (,50 000/ml; approxi-
mately 11% of patients captured here) are usually not
eligible to participate in clinical trials with JAK
inhibitors. Thrombocytopenia is a common side
effect of JAK inhibitors,31 and spontaneous bleeding
could have fatal consequences for patients with very
low platelets count. However, pacritinib (selective
inhibitor for JAK2 and FLT3) was shown to alleviate
MF-associated splenomegaly and constitutional
symptoms in a Phase II clinical study, where seven
out of 34 patients had platelet counts ,50 000/ml.39
Different JAK inhibitors under clinical development
are selective for different kinases. It remains unclear
how the efficacy and side-effects of the JAK inhibitors
can be attributed to the inhibition of individual JAK
family members, but it could be envisaged that MF
patients may benefit from future rational drug combi-
nations that target multiple signaling pathways.25,40
Ruxolitinib has been tested on Int-2 and High risk
MF patients with platelet counts above 100 000/ml
and a spleen size over 5 cm in Phase III clinical
trials.33,34 Data available to date suggest that
ruxolitinib may improve survival versus placebo or
best available therapy.41–43 The main drug side-
effects were thrombocytopenia, anemia and diarrhea.
Due to the thrombocytopenic effect, ruxolitinib is not
routinely indicated for patients with less than 100 000
platelets/ml. However, ruxolitinib is currently being
tested in Phase Ib/II clinical trials in thrombocyto-
penic MF patients (platelet counts of 50 000–
100 000/ml) with positive results (reduction in sple-
nomegaly and constitutional symptoms).44
In our survey, out of the total population with
spleen size §5 cm under the costal margin and a
platelet count above 50 000/ml, almost all patients
(97%) were Intermediate to High risk (IPSS and
DIPSS). Three quarters IPSS and half DIPSS
patients were Int-2 and High risk, respectively.
While about one-third of these higher risk patients
would be considered eligible for transplantation
based on age, the remaining high risk patients could
thus potentially benefit from treatment with hydro-
xyurea or JAK inhibitors.25–27 If we applied the
inclusion criteria for the Comfort trials33,34 to the MF
patient population included in the current study, 72/
250 (29%) patients would qualify (Int-2 and High risk
categories [IPSS], spleen size§5 cm below the costal
margin and a platelet count §100 000/ml). If we
expanded this selection to include the Int-1 risk
category (IPSS) and all patients Intermediate to High
risk (IPSS) with a platelet count §50 000/ml, the
proportion of MF patients captured by this survey
who could potentially benefit from treatments with
JAK inhibitors would be as high as 44% (111/250).
Figure 3 Distribution of patients according to spleen size and platelet count: (A) number of patients; (B) percentages.
Figure 2 Distribution of patients (%) according to IPSS or
DIPSS risk categories and platelet count.
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The management of anemia, a major symptom of
MF and a side-effect of some of the tested JAK
inhibitors, can be a challenging aspect of treating
patients with MF.33,34,45 MF-associated anemia is
currently treated with ESAs, prednisone, danazol,
thalidomide or lenalidomide.31 Pomalidomide, a
derivative of thalidomide, was shown to be active in
the treatment of anemia in Phase I/II trials,46 but in a
recently conducted Phase III trial comparing low
dose pomalidomide versus placebo in RBC-dependent
MF patients, the primary endpoint, RBC-transfusion
independence, has not been reached.47 Clinical trials
are currently underway to test the possible benefits of
combining ruxolitinib with anti-anemia drugs (thali-
domide, lenalidomide, danazol, or ESAs).48 A limita-
tion of the current study is the lack of information on
anemia and transfusion-dependency, which lowers our
understanding of the potential impact of anemia in the
MF patients captured in this survey. Although
hemoglobin concentration (,10 g/dl) was used as a
predictive risk factor in assessing IPSS and DIPSS risk
groups, the pre-defined questions of this survey did not
target the distribution of patients according to
hemoglobin concentration or transfusion-dependency.
In conclusion, the results of this survey provide
important insight into the characteristics of the
Belgian MF population, according to specific disease
parameters. They also suggest that a large proportion
of these patients, particularly in the Intermediate to
High risk categories, could benefit from treatment
with investigational drugs under development. These
new treatments, although they offer promise in the
improvement in quality of life of certain MF patients,
still do not offer a cure and may not yet be
appropriate for all patients.
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